Statins do not meaningfully lower lipoprotein(a), commonly written as Lp(a). A systematic review and meta-analysis of 39 studies covering more than 24,000 participants found that statin therapy produced an average absolute change of just 1.1 mg/dL compared to placebo, a difference too small to matter clinically. Some laboratory evidence even suggests statins nudge Lp(a) in the wrong direction. This makes Lp(a) an outlier among blood lipids, most of which respond readily to the same drugs, and it raises practical questions for anyone whose doctor has flagged a high level.
Why Lp(a) Barely Budges on Statins
Statins work by blocking an enzyme in the liver that cells need to make cholesterol. When the liver’s cholesterol supply drops, it compensates by pulling LDL particles out of the bloodstream. That is why LDL cholesterol falls so reliably on statin therapy. Lp(a) particles share some structural overlap with LDL, but the liver handles them differently. The particle’s signature protein, apolipoprotein(a), is encoded by the LPA gene, and production of that protein is heavily driven by genetics rather than by the cholesterol-sensing machinery statins target.
Cell studies have shown that exposing liver cells to atorvastatin actually increases expression of the LPA gene and production of the apolipoprotein(a) protein. In other words, the same drug that powerfully suppresses LDL cholesterol may gently ramp up the machinery that makes Lp(a). That finding comes from lab dishes, not patients, so the real-world magnitude is unclear. But it aligns with what large trials show: on average, Lp(a) does not go down on a statin and, in some people, ticks upward.
Does the Type or Dose of Statin Matter
A reasonable follow-up question is whether switching statin brands or pushing the dose higher would help. The same meta-analysis broke results down by individual statin and found no winner. Atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin all failed to produce a statistically significant change in Lp(a) compared to placebo. Low-, intermediate-, and high-intensity regimens also showed no meaningful Lp(a) reduction. The one wrinkle is that high-intensity statin therapy showed a slightly larger absolute Lp(a) change in the upward direction compared to lower intensities, though none of the changes crossed into clinically important territory.
A smaller head-to-head study comparing rosuvastatin and atorvastatin, alone and in combination with other lipid drugs, did report Lp(a) reductions, but the combination arms included extended-release niacin, which has its own Lp(a)-lowering effect. The bottom line across the evidence is that no statin, at any dose, reliably lowers Lp(a) on its own.
Should You Worry About a Statin-Driven Lp(a) Increase
If statins can push Lp(a) up slightly, should people with already-high Lp(a) think twice about starting one? The evidence says no. Most patients experience either no change or only a mild increase in Lp(a) after starting statin therapy, and that small bump does not appear to increase the risk of cardiovascular events. One study of patients with coronary artery disease who were on statins for secondary prevention put it bluntly: reducing LDL cholesterol by about 39 mg/dL provides a cardiovascular benefit comparable to what you would get from reducing Lp(a) by roughly 68 mg/dL. Statins deliver that LDL reduction easily, so the net trade-off overwhelmingly favors staying on them.
The practical advice from researchers and guidelines is consistent: do not let a modest Lp(a) increase scare you away from a drug that aggressively lowers your single biggest modifiable lipid risk factor. Instead, if your Lp(a) is high, treat it as a separate problem that needs its own strategy.
When High Lp(a) Becomes a Problem Despite Statins
For some patients, high Lp(a) represents a leftover risk that persists even after LDL cholesterol has been driven to target levels. Researchers call this “residual risk,” and it is increasingly recognized as a real clinical issue. A study tracking statin-treated patients after a first ischemic stroke found that those with on-statin Lp(a) levels at or above 70 mg/dL had roughly two and a half times the risk of recurrent vascular events compared to patients with lower levels. That elevated risk held even among patients whose LDL cholesterol was well controlled below guideline targets.
Imaging data tells a similar story. In patients with coronary artery disease receiving aggressive LDL-lowering therapy, increases in Lp(a) independently predicted progression of coronary plaque, regardless of how much LDL cholesterol had dropped. These findings highlight Lp(a) as a residual risk factor in statin-treated patients, one that LDL control alone cannot fully address.
What Lp(a) Actually Is and Why It Resists So Many Interventions
Lp(a) is essentially an LDL-like particle with an extra protein, apolipoprotein(a), tethered to it. What makes it unusual among lipid markers is how tightly its blood level is controlled by your DNA. The LPA gene contains a highly variable region that produces over 40 different-sized versions of the apolipoprotein(a) protein. People who carry smaller isoforms can have median Lp(a) concentrations up to five times higher than people with larger isoforms. Because the gene, not your diet or exercise habits, sets the baseline, Lp(a) stays remarkably stable throughout adult life for any given person.
This genetic grip also explains why so many interventions fail. A particle whose production rate is hardwired into your liver’s gene expression doesn’t respond to the usual tricks that rearrange how the liver handles cholesterol. Statins manipulate cholesterol metabolism; Lp(a) production marches to a different drum.
Can Diet or Exercise Lower Lp(a)
Given that statins don’t help, many people wonder whether lifestyle changes might. The evidence is discouraging. Studies extending from 12 weeks to four years show that moderate exercise training does not change Lp(a) levels, even when fitness improves and other lipid markers get better. Cross-sectional studies comparing active and sedentary populations also find no consistent association between physical activity and Lp(a).
Diet tells a similar story. Standard low-fat dietary changes recommended for heart health and weight loss have little effect on Lp(a). In fact, some evidence suggests that diets lower in saturated fat can modestly shift Lp(a) in the opposite direction from LDL cholesterol, meaning LDL goes down but Lp(a) nudges up. The overall picture from randomized controlled trials is that diet and exercise, while beneficial for many cardiovascular risk factors, are not effective tools for managing Lp(a).
Drugs That Actually Lower Lp(a)
If statins, diet, and exercise leave Lp(a) alone, what works? Two categories of drugs show genuine effects, though they differ enormously in magnitude.
PCSK9 Inhibitors
PCSK9 inhibitors, the injectable antibody drugs evolocumab and alirocumab, were developed primarily to lower LDL cholesterol in patients who need more reduction than statins alone can deliver. As a side benefit, they also lower Lp(a). A meta-analysis of randomized controlled trials found that PCSK9 inhibitors reduce Lp(a) by an average of about 27%. In one trial, evolocumab reduced Lp(a) by a median of roughly 27% at 48 weeks. The mechanism appears to involve speeding up the rate at which the liver clears Lp(a) particles from the bloodstream, possibly by upregulating receptors that can grab Lp(a) or by reducing competition between Lp(a) and LDL for those same receptors.
A 27% reduction is meaningful but limited. For someone whose Lp(a) is, say, 150 mg/dL, a 27% drop still leaves them well above the thresholds most guidelines consider elevated. PCSK9 inhibitors are a useful add-on, especially for patients already on statins who have both high LDL and high Lp(a), but they are not a complete solution for Lp(a) on their own.
RNA-Based Therapies in Development
The most exciting development for people with high Lp(a) is a new class of drugs that attack the problem at its genetic source. These are RNA-based therapies, including antisense oligonucleotides and small interfering RNAs, that intercept the messenger RNA from the LPA gene before the liver can use it to build apolipoprotein(a). Several candidates are in clinical trials, including pelacarsen, olpasiran, zerlasiran, lepodisiran, and SLN360.
The reductions seen so far are dramatic. In the phase 2 OCEAN(a)-DOSE trial, olpasiran produced dose-dependent Lp(a) reductions ranging from about 71% at the lowest dose to over 100% (meaning levels dropped below the starting point by more than the starting value, reflecting the placebo group’s slight rise) at higher doses, with no significant safety concerns. These are the kind of reductions that could plausibly change cardiovascular outcomes for people whose Lp(a) is driving their risk. Large cardiovascular outcomes trials are ongoing to determine whether these Lp(a) reductions actually translate into fewer heart attacks and strokes.
Niacin (vitamin B3) has long been known to lower Lp(a), but its practical usefulness has been limited. Side effects like flushing make it poorly tolerated, and its effectiveness in reducing Lp(a)-related cardiovascular risk remains unclear. It is not widely recommended for this purpose today.
Who Has the Highest Lp(a) Levels
Lp(a) levels vary substantially across racial and ethnic groups, a pattern driven largely by differences in LPA gene variants. Decades of research have established a consistent hierarchy: Black individuals tend to have the highest Lp(a) levels, followed by South Asians, then White individuals, with Hispanic and East Asian populations generally having the lowest levels. A large study examining disaggregated racial and ethnic subgroups found that over 62% of non-Hispanic Black patients had Lp(a) levels at or above 50 mg/dL, compared to about 31% of Mexican patients. After adjusting for other factors, Black individuals had roughly 2.5 times the odds of having elevated Lp(a) compared to the reference group.
These disparities matter for screening. If you belong to a group with higher average Lp(a) levels and you have a family history of early heart disease, the case for getting your Lp(a) measured at least once is stronger. Lp(a) is not part of a standard lipid panel, so you typically have to request it or have a doctor order it specifically.
Getting Tested and Understanding Your Number
One reason Lp(a) has been slow to enter routine clinical practice is that measuring it is surprisingly tricky. The apolipoprotein(a) protein comes in many sizes, and different lab assays can give different results depending on which size variants a person carries. Challenges include the use of appropriate calibrators, standardization of protocols, traceability, and reporting units. Some labs report Lp(a) in mg/dL, others in nmol/L, and the two units are not interchangeable through a simple conversion because of the particle-size variability.
Despite these measurement headaches, clinical guidelines are increasingly moving toward universal screening. Expert groups now advocate measuring Lp(a) at least once in all adults, with the reasoning that since levels are largely stable over a lifetime, a single measurement tells you whether this is a risk factor you need to manage. Until cardiovascular outcomes trials for the new Lp(a)-specific drugs are complete, guidelines recommend that people with high Lp(a) focus on aggressively managing every other modifiable risk factor: LDL cholesterol, blood pressure, blood sugar, smoking, and weight.
Lp(a) Across Species and the Question of Why It Exists
One oddity that intrigues researchers is that Lp(a) has a very limited distribution across the animal kingdom. It is found in humans, Old World primates, and, curiously, the European hedgehog, but not in most other mammals. That patchy distribution suggests Lp(a) is not just evolutionary baggage. One hypothesis is that Lp(a) originally served a protective role after injury, since the particle can bind to immune cells and platelets and participate in wound-healing processes related to fibrin activation. If that is true, what helped our ancestors survive cuts and trauma in a pre-modern world may now be working against us in an era of chronic cardiovascular disease. The same particle that promotes clot formation at a wound site can accelerate plaque buildup in arteries over decades.
This evolutionary framing also helps explain why Lp(a) levels are so resistant to change. If the trait was under positive selection pressure for millions of years, the body has no reason to have built easy off-switches. Drugs that want to lower Lp(a) essentially have to override a system that evolution spent a long time optimizing, which is why the RNA-based therapies that intercept the gene’s message before it is read are the first interventions to achieve truly large reductions.